{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:43:54Z","timestamp":1777013034578,"version":"3.51.4"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical &amp; Translational Med"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A multi\u2010centre, 2\u2010part, phase II study assessed adding rezvilutamide (a novel androgen receptor antagonist) to docetaxel in abiraterone\u2010refractory, metastatic castration\u2010resistant prostate cancer (mCRPC) patients who were naive to chemotherapy. Herein, we report results from part 1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Part 1 encompassed both dose\u2010escalation and dose\u2010expansion phases. Eligible patients received oral rezvilutamide (160\/240\u00a0mg, once daily [QD]) plus intravenous docetaxel (75\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , on the first day of every 3\u2010week cycle) for more than 10 cycles, followed by maintenance with rezvilutamide monotherapy (240\u00a0mg, QD). Rezvilutamide was administered daily starting from the second day of cycle 1. Docetaxel was co\u2010administered with oral prednisone at 5\u00a0mg twice daily. Safety served as the primary objective in Part 1.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2, December 2020, to 5, August 2021, 36 patients were eligible for enrolment (18 patients with rezvilutamide 160\u00a0mg plus docetaxel and 18 patients with rezvilutamide 240\u00a0mg plus docetaxel). No one experienced dose\u2010limiting toxicity. 32 (88.9%) patients experienced grade 3 or higher treatment\u2010related adverse events. At week 12, 67.7% of the 31 evaluable patients showed a response in prostate\u2010specific antigen (PSA) levels. Among all 36 patients, the median times were 10.5 months (95% CI: 5.6\u201314.1) for PSA progression, 13.8 months (95% CI: 8.4\u201319.2) for radiological progression\u2010free survival and 16.2 months (95% CI: 12.9\u201322.5) for overall survival. The limitations were a small sample size and a non\u2010randomised design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rezvilutamide plus docetaxel followed by maintenance with rezvilutamide monotherapy demonstrated good tolerability and promising efficacy in chemotherapy\u2010naive, abiraterone\u2010refractory, mCRPC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ctm2.70649","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:01:48Z","timestamp":1776322908000},"source":"Crossref","is-referenced-by-count":0,"title":["Rezvilutamide plus docetaxel in chemotherapy\u2010naive metastatic castration\u2010resistant prostate cancer patients after progression on abiraterone: A multi\u2010centre, open\u2010label, phase II trial"],"prefix":"10.1002","volume":"16","author":[{"given":"Zhenhua","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Urology Institute of Urology West China Hospital Sichuan University  Chengdu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology Institute of Urology West China Hospital Sichuan University  Chengdu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery Hunan Cancer Hospital  Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery Hunan Cancer Hospital  Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Uro\u2010Oncology Chongqing University Cancer Hospital  Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Urological Oncology Sichuan Cancer Hospital  Chengdu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dexin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Urology Second Affiliated Hospital of Anhui Medical University  Hefei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology The First Affiliated Hospital of the Chinese People's Liberation Army Medical University  Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dahong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology Zhejiang Provincial People's Hospital  Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urological Oncology Sichuan Cancer Hospital  Chengdu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology Second Affiliated Hospital of Anhui Medical University  Hefei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Urology Zhejiang Provincial People's Hospital  Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Development\u2010Oncology Jiangsu Hengrui Pharmaceuticals Co., Ltd  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqin","family":"Lin","sequence":"additional","affiliation":[{"name":"Clinical Statistics Jiangsu Hengrui Pharmaceuticals Co., Ltd  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yike","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Jiangsu Hengrui Pharmaceuticals Co., Ltd  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Feng","sequence":"additional","affiliation":[{"name":"Clinical Trial Centre and National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs West China Hospital Sichuan University  Chengdu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Urology Institute of Urology West China Hospital Sichuan University  Chengdu China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40779\u2010025\u201000599\u2010y"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000\u20109604.2023.04.08"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.11.038"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010018\u201006811\u2010z"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010018\u201006845\u20103"},{"key":"e_1_2_11_8_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)","author":"National Comprehensive Cancer Network","year":"2024"},{"key":"e_1_2_11_9_1","volume-title":"Guidelines of Chinese Society of Clinical Oncology (CSCO)","author":"Chinese Society of Clinical Oncology","year":"2023"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(19)30688\u20106"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22844"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2015.01.004"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv070"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2014.03.010"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds119"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.08.002"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6548"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201015\u20100269"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.Can\u201011\u20101417"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.Can\u201009\u20101504"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201015\u20102638"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916\u2010022\u201002263\u2010x"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15528"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(22)00507\u20101"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(10)60172\u20109"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010019\u201039589\u2010"}],"container-title":["Clinical and Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ctm2.70649","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ctm2.70649","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ctm2.70649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:04:37Z","timestamp":1777010677000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ctm2.70649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/ctm2.70649"],"URL":"https:\/\/doi.org\/10.1002\/ctm2.70649","archive":["Portico"],"relation":{},"ISSN":["2001-1326","2001-1326"],"issn-type":[{"value":"2001-1326","type":"print"},{"value":"2001-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"e70649"}}